Eli Lilly and Company (BVMF:LILY34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 5.45T +52.0% |
| Revenue (ttm) | 412.73B +49.6% |
| Net Income | 138.38B +93.6% |
| EPS | 154.33 +94.8% |
| Shares Out | n/a |
| PE Ratio | 39.40 |
| Forward PE | 29.73 |
| Dividend | 0.77 (0.38%) |
| Ex-Dividend Date | Aug 13, 2026 |
| Volume | 15,935 |
| Open | 205.03 |
| Previous Close | 203.50 |
| Day's Range | 201.60 - 205.03 |
| 52-Week Range | 126.72 - 223.07 |
| Beta | 0.51 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
US FDA approves Lilly's Mounjaro to reduce cardiovascular risk
Eli Lilly said on Friday the U.S. FDA has approved its diabetes drug Mounjaro to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high ri...
Eli Lilly announces FDA approval of Mounjaro to reduce cardiovascular risk
Eli Lilly (LLY) and Company announced that the U.S. FDA approved Mounjaro, a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse cardiovascular events, including…
FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
Mounjaro is the first and only GIP and GLP-1 receptor agonist proven to lower heart attack, stroke or cardiovascular death risk in adults with type 2 diabetes at high risk for these events – in additi...
Eli Lilly Stock (LLY) Pulls Back After Hitting Record High
The stock had rallied after the company’s latest earnings.
White House to announce new drug pricing deals with biotechs, Bloomberg News reports
U.S. President Donald Trump's administration is planning to announce a new round of drug-pricing agreements with midsize biotech companies on Monday, Bloomberg News reported on Wednesday, c...
Eli Lilly Stock (LLY) in Focus as Alzheimer’s Blood Test Gets FDA Approval
The test has already been approved in Europe.
Eli Lilly announces results from Zepbound healthcare costs study
Eli Lilly (LLY) announced results from a real-world study of adults over 55 with overweight or obesity, which found that staying on Zepbound for weight management lowered healthcare costs over…
Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
First-of-its-kind study shows sustained Zepbound use in older adults with obesity lowers costs, reinforcing the potential value of the Medicare GLP-1 Bridge program Individuals treated with Zepbound h...
Eli Lilly Stock (LLY) Rattled as Companies Decline to Cover Weight-Loss Drug Costs
Some companies view obesity medications as optional treatments.
PepsiCo ending coverage for prescription weight-loss drugs, Bloomberg reports
Some PepsiCo (PEP) employees were notified this week that weight-loss drugs such as Novo Nordisk’s (NVO) Wegovy and Eli Lilly’s (LLY) Zepbound will no longer be covered by their company…
Eli Lilly Stock (LLY) in Focus as Hedge Fund Titan Ken Griffin Quadruples Position
Citadel now has a stake worth $1.1 billion.
FDA Clears Roche And Eli Lilly's Alzheimer's Blood Test
The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify symptoms related to Alzheimer's disease in patients over age 55, Roche said on Monday m...
Eli Lilly Stock (LLY) Falls despite FDA Approval for Alzheimer’s Blood Test Developed with Roche
Shares in Eli Lilly ($LLY) edged lower to around $1,243 per share on Monday morning. This came even after the U.S. Food and Drug Administration (FDA) approved a blood test…
FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly
The Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed by Roche and Eli Lilly.
Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance
The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help identify signs of Alzheimer's disease in people aged 55 and older with cognitive decline.
Eli Lilly Launches Foundayo Weight-Loss Pill in U.K.
The once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event of at least one weight-related health condition.
Eli Lilly launches oral weight-loss pill Foundayo in UK
Eli Lilly said on Monday it has launched its oral pill, Foundayo, in the UK for weight management and type 2 diabetes, making it the first country in Europe where the treatment is available.
Eli Lilly Stock (LLY) Hits All-Time High as Post-Earnings Rally Continues
The drug maker is seeing accelerating sales of its weight-loss medications.
Eli Lilly files six new lawsuits in effort to shutdown retatrutide black market
Eli Lilly (LLY) escalated its continued fight to protect patients from the black market for retatrutide, filing six new lawsuits against U.S. entities selling black-market products in addition to havi...
OmniAb announces collaboration and license agreement with Eli Lilly
OmniAb (OABI) announced a global collaboration and license agreement with Eli Lilly and Company (LLY) for a new ion channel program. The collaboration leverages OmniAb’s technology platform and expert...
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
Novo CEO says obesity market won't be winner-take-all battle with Lilly
Novo Nordisk CEO Mike Doustdar said investors are underestimating the demand for differentiation among obesity drugs, and that new treatment options like pills will keep it from becoming a winner-tak...
Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'
Novo Nordisk CEO Mike Doustdar defended the drugmaker's decision to sue rival Eli Lilly over its weight-loss drug advertising. "I am a big fan of competition.